In 2025, we progressed with the disciplined execution of our One Lonza strategy, first introduced at our December 2024 Investor Update. The One Lonza strategy is designed to advance our vision, to be the pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology and lean manufacturing.
As we continue to focus on the implementation of our strategy, our success is underpinned by our purpose and values, which contribute to our One Lonza culture.
Our purpose is to turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. This is our reason for being and defines the positive impact we have on the world around us. Alongside this shared purpose, our global colleague community is united by five core values that guide how we work together and how we engage with partners and the wider world.
These values form the foundation for our unified One Lonza culture, which is recognized and respected across our global network. This will continue to define our future success, not just in what we achieve, but also in how we achieve it.
The Lonza Engine® 1 sits at the heart of our strategy. It combines our unique set of core competencies that work together to deliver outstanding, long-term value. The Lonza Engine® comprises five key components.
Like a finely tuned engine, each component works in harmony to drive complementary strategic outcomes that drive lasting competitive advantage. The whole of the Lonza Engine® is greater than the sum of its parts.
Throughout the year, we balanced the disciplined execution of our One Lonza strategy with the agility needed to navigate the external developments in our industry and the world around us. A combination of planned and adaptive strategic approaches remains essential to maintaining our leadership position and continuing to ensure long-term performance and value creation.
In support of the One Lonza strategy, we implemented our simplified and streamlined operating model on 1 April 2025. Comprising three CDMO Business Platforms, this new structure is designed to enhance customer experience, provide scalability for future growth and strengthen our end-to-end multimodality offering:
The implementation of this new operating model has worked to strengthen all components of the Lonza Engine®. For example, the removal of the business unit layer within our updated organizational structure has enabled our high-performance teams to work more effectively together across Business Platforms. Additionally, the creation of Strategic Enterprise Account Management as a new Group Function enhances our ability to foster unparalleled customer partnerships and provide a seamless and consistent One Lonza customer experience. The streamlined structure also strengthens the scalability of our business model, supporting sustainable growth and enhancing our plug-and-play investment and integration capabilities.
Our plug-and-play investment and integration capabilities and end-to-end execution excellence were further strengthened by a combination of organic growth and strategic bolt-on acquisitions. Our highly potent API (HPAPI) plant in Visp (CH) made good progress in ramping up and commencing commercial operations. At our new large-scale mammalian drug substance facility, also located in Visp, GMP operations are now underway and commercial production is set to ramp up from 2026 onwards.
Our Vacaville (US) site – acquired in October 2024 – continued to successfully integrate into our global network in 2025. The site maintained strong operational execution and an excellent quality track record while preparing for new product introductions. The first phase of capital expenditure commenced at the site in 2025, with additional investments to follow in the next two to three years. These integration and investment efforts will ensure that Vacaville is fully equipped to deliver next-generation therapies as a critical part of our leading scientific and technological ecosystem.
In 2025, we secured several major customer contracts that highlight both the strength of our leading scientific and technological ecosystem, and our unparalleled customer partnerships. This included an agreement with Ethris for the development of spray-dried mRNA vaccines, Iconovo for the development of an intranasal biologic, Exogenous for the development of its lead exosome-based candidate, and RION for the manufacture of exosome-based drug substance. We also negotiated several new contracts for mammalian manufacturing in Vacaville (US), as the site advances its transition to a multi-product CDMO facility – with further signings expected in 2026. The diversity of modalities represented across these programs demonstrates the breadth of our specialist expertise and further reinforces how the One Lonza strategy is strengthening our position as a global partner of choice for complex therapeutic technologies, across all development and manufacturing stages.
